Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DW16011 is an oral fixed-dose combination syrup used for the treatment of acute bronchitis. It contains three active pharmaceutical ingredients with distinct mechanisms of action: - Ammonium chloride (an expectorant) - Chlorpheniramine maleate (an antihistamine) - Dihydrocodeine tartrate (an antitussive/opioid cough suppressant) DW16011 is designed to relieve symptoms associated with acute bronchitis, such as cough and sputum production, by combining these agents to provide expectorant, antihistaminic, and antitussive effects. It has been studied both as a monotherapy and as a component of the combination product DW1601 (which also includes Pelargonium sidoides extract) in clinical trials for acute bronchitis. It is developed by Daewon Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DW16011.